A5088046525- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Nanoplatforms for cancer theranostics
- Chemical Synthesis and Reactions
- Click Chemistry and Applications
- Advanced biosensing and bioanalysis techniques
- Immune cells in cancer
- Chemokine receptors and signaling
- Peptidase Inhibition and Analysis
- Radical Photochemical Reactions
- Advanced Nanomaterials in Catalysis
- Signaling Pathways in Disease
- Immune Cell Function and Interaction
- Acute Lymphoblastic Leukemia research
- Sulfur-Based Synthesis Techniques
- Adenosine and Purinergic Signaling
University of Edinburgh
2022-2025
MRC Centre for Regenerative Medicine
2023-2025
Centre for Inflammation Research
2022-2025
ETH Zurich
2023
Increased levels of tumor-associated macrophages (TAMs) are indicators poor prognosis in most cancers. Although antibodies and small molecules blocking the recruitment to tumors under evaluation as anticancer therapies, these strategies not specific for macrophage subpopulations. Herein we report first enzyme-activatable chemokine conjugates effective targeting defined subsets live tumors. Our constructs exploit high expression receptors (e.g., CCR2) activity cysteine cathepsins TAMs target...
Immunosuppressants are clinically approved drugs to treat the potential rejection of transplanted organs and require frequent monitoring due their narrow therapeutic window. Immunophilins small proteins that bind immunosuppressants with high affinity, yet there no examples fluorogenic immunophilins application as optical biosensors for immunosuppressive in clinical biosamples. In present work, we designed novel diazonium BODIPY salts site-specific labeling tyrosine residues peptides via...
Photocatalysts are excellent scaffolds for the light-mediated control of bioactive molecules. Current photocatalytic structures not compatible with genetic encoding and therefore cannot be directly incorporated into sequences native proteins. Herein, we developed new amino acids incorporating Si-rosamine units, introduced them via aminoacylation tRNAs specific positions different proteins to enable targeted reactions in defined populations immune cells.
Drug resistance in B cell leukemia is characterized by the coexpression of CXCR5 and CXCR3 chemokine receptors, making it a valuable biomarker for patient stratification. Herein, we report novel platform activatable chemokines to selectively image drug-resistant leukemic cells first time. The C-terminal derivatization human CXCL13 CXCL10 with bioorthogonal tetrazine-BODIPY BCN groups retained binding internalization via their cognate receptors enabled rapid fluorescence labeling CXCR5+...
// Michael R. Mortensen 1 , Jacqueline Mock Marco Bertolini Stringhini Catalano and Dario Neri Department of Chemistry Applied Biosciences (D-CHAB), Institute for Pharmaceutical Sciences (IPW), 8093 Zurich, Switzerland Correspondence to: Mortensen, email: michael.mortensen@pharma.ethz.ch Keywords: immunotherapy; immunocytokines; EDB fibronectin; antibody-cytokine fusion proteins; engineered cytokine Received: July 30, 2020 Accepted: September 24, Published: November 03, Copyright: © et al....
Drug resistance in B cell leukemia is characterized by the co-expression of CXCR5 and CXCR3 chemokine receptors, making it a valuable biomarker for patient stratification. Herein we report novel platform activatable chemokines to selectively image drug-resistant leukemic cells first time. The C-terminal derivatization human CXCL13 CXCL10 with bioorthogonal tetrazine-BODIPY BCN groups retained binding internalization via their cognate receptors enabled rapid fluorescence labeling CXCR5+...
Increased levels of tumor-associated macrophages (TAMs) are indicators poor prognosis in most cancers. Although antibodies and small molecules blocking the recruitment to tumors under evaluation as anticancer therapies, these strategies not specific for macrophage subpopulations. Herein we report first enzyme-activatable chemokine conjugates effective targeting defined subsets live tumors. Our constructs exploit high expression receptors (e.g., CCR2) activity cysteine cathepsins TAMs target...
The targeted delivery of bioactive proteins, such as cytokines, for cancer immunotherapy approaches mostly relies on antibodies or antibody fragments. However, fusion proteins may display low tissue penetration due to a large molecular size. Small molecule ligands with high affinity toward tumor-associated antigens provide promising alternative the selective cytokines tumor lesions. We developed one-pot procedure site-specific thiazolidine formation between an aldehyde bearing small and in...